

Anti-hCTLA4-hIgA2

Monoclonal human IgA2 antibody against human CTLA-4

Catalog # hctla4-mab7

For research use only, not for diagnostic or therapeutic use

Version # 15D27-MM

PRODUCT INFORMATION

Content: 100 µg anti-hCTLA4-hIgA2, purified antibody, provided azide-free and lyophilized

Specificity: cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)

Isotype: Human IgA2

Source: CHO cells

Formulation: 0.2 µm filtered solution in a sodium phosphate buffer with glycine, saccharose and stabilizing agents.

Antibody resuspension

Add 1 ml of sterile water to obtain a concentration of 0.1 mg/ml.

Storage

- Product is shipped at room temperature. Store lyophilized antibody at -20 °C. Lyophilized product is stable for at least 1 year.

- Reconstituted antibody is stable for 1 month when stored at 4 °C and for 1 year when aliquoted and stored at -20 °C. Avoid repeated freeze-thaw cycles.

Quality control

- Binding of anti-hCTLA4-hIgA2 to human CTLA-4 has been tested using flow cytometry.

- The complete sequence of this antibody has been verified.

- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

DESCRIPTION

Anti-hCTLA4-hIgA2 features the constant region of the human IgA2 isotype and the variable region of ipilimumab. Ipilimumab is a fully human IgA2 monoclonal antibody that targets CTLA-4 (also known as CD152), a negative regulator of T cell activation. By binding CTLA-4, ipilimumab inhibits negative signals that physiologically downregulate T cell activation and exerts its therapeutic activity by upregulating the antitumor activity of T lymphocytes^{1, 2}. In addition, Ipilimumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) and TNF-α production³. Ipilimumab has been approved by the FDA for the treatment of unresectable or metastatic melanoma. Ipilimumab is undergoing clinical trials for other types of cancers, including lung cancer⁴.

Anti-hCTLA4-hIgA2 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with peptide M.

1. **Grosso JF. & Jure-Kunkel MN., 2013.** CTLA-4 blockade in tumor models: an overview of preclinical and translational research. *Cancer Immun.* 13:5. 2. **Maio M. et al., 2013.** Update on the role of ipilimumab in melanoma and first data on new combination therapies. *Curr Opin Oncol.* 25(2):166-72. 3. **Laurent S. et al., 2013.** The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. *J Transl Med.* 11:108. 4. **Tomasini P., 2012.** Ipilimumab: its potential in non-small cell lung cancer. *Ther Adv Med Oncol.* 4(2): 43-50.

ANTIBODY ISOTYPE COLLECTION

For your research, InvivoGen provides an anti-hCTLA4 isotype family. This isotype family consists of monoclonal antibodies comprising the variable region of ipilimumab, and the constant region of three different human isotypes; IgG1, IgG4, and IgA2. The isotypes differ in their functional locations and effector functions, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), as presented in the table below.

Name	Description
Human IgG1	Most abundant IgG present in serum High CDC, high ADCC
Human IgG4	Least common IgG present in serum No CDC, low ADCC
Human IgA2	Major class in secretions, oligomeric forms, highly resistant to enzymatic degradation. No CDC, low ADCC

RELATED PRODUCTS

Product	Catalog Code
Anti-hCTLA4-hIgG1	hctla4-mab1
Anti-hCTLA4-hIgG4 (S228P)	hctla4-mab14

Other antibody isotype families are available, such as Anti-hCD20, Anti-hPD1 and Anti-βGal (control).

For more information visit www.invivogen.com/antibody-isotypes.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3-622-34-80

E-mail: info@invivogen.com